Prevalence of Musculoskeletal Symptoms in the Cambridge NIHR BioResource

November 11, 2020 updated by: Professor Andrew McCaskie, Cambridge University Hospitals NHS Foundation Trust

Musculoskeletal diseases, such as osteoarthritis, represent a large proportion of the global burden of disease with hip and knee osteoarthritis alone being the 11th greatest cause of disease burden.

The purpose of this study is to determine the level of musculoskeletal symptoms in members of the Cambridge National Institute for Health Research (NIHR) BioResource and see if this is associated with their possession of genetic markers that have been identified as being associated with osteoarthritis.

This will allow us to determine the real level of musculoskeletal symptoms in this large cohort of volunteers and provide basic information that could be used to facilitate further musculoskeletal research in the NIHR BioResource population.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

All active members of the Cambridge NIHR BioResource will be approached.

They will be sent an email outlining the purpose of the study and asking that if they would like to take part to please complete the online questionnaire which will be linked to in the email.

For those individuals who agree to participate and complete the questionnaire, the Cambridge NIHR BioResource will provide the genetic marker information it already holds for specific markers that are known to be associated with osteoarthritis.

Study Type

Observational

Enrollment (Anticipated)

5000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All members of the Cambridge NIHR BioResource

Description

Inclusion Criteria:

  • Member of the NIHR BioResource
  • Willing to consent to participate

Exclusion Criteria:

  • Previous self-report of osteoarthritis on joining BioResource

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Member of BioResource
Any BioResource member who consents to take part in the study and completes the study questionnaire.
Other: Questionnaire including MSK-HQ (Musculoskeletal Health Questionnaire)
A questionnaire regarding musculoskeletal past medical history and current symptoms.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
MSK Symptom Levels
Time Frame: 3 months
Musculoskeletal Symptoms in respondents
3 months
Osteoarthritis genetic marker
Time Frame: 6 months
Possession (or not) of specific genetic markers for osteoarthritis (obtained from information already held by the NIHR BioResource)
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
MSK Cohort
Time Frame: 6 months
Identification of those with particular musculoskeletal injuries and conditions for future studies
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cambridge University Hospitals NHS Foundation Trust

Collaborators

University of Cambridge

Investigators

  • Principal Investigator: Andrew McCaskie, University of Cambridge

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

November 1, 2020

Primary Completion (Anticipated)

April 1, 2021

Study Completion (Anticipated)

August 1, 2021

Study Registration Dates

First Submitted

November 11, 2020

First Submitted That Met QC Criteria

November 11, 2020

First Posted (Actual)

November 17, 2020

Study Record Updates

Last Update Posted (Actual)

November 17, 2020

Last Update Submitted That Met QC Criteria

November 11, 2020

Last Verified

November 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • A095310

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

IPD Plan Description

Sharing of participant level data does not fall within the consent or ethical approval of the study.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Musculoskeletal Diseases

Clinical Trials on Questionnaire including MSK-HQ (Musculoskeletal Health Questionnaire)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe